The $26,500 Mirage: Why the New Alzheimer’s Drugs Are a Logistical Nightmare

The headlines promised a cure, but the reality is bi-weekly infusions, brain bleeding risks, and a system built to break your budget.

If you read the front-page headlines last year, you might think we finally beat Alzheimer’s. Pharmaceutical giants popped champagne over drugs like Leqembi and Kisunla, promising to claw back precious months of memory. But they forgot to mention the bi-weekly hospital visits, the mandatory brain scans, and the very real chance of brain bleeding. For most families, these drugs aren't a miracle; they're a second full-time job with a massive price tag.

More from Inside the Industry →   ·   Back to Perch   ·   Browse all stories